

LEONE ASSET MANAGEMENT, INC.
Initial Company Information and Disclosure Statement
June 26, 2017

Part A General Company Information

Item I: *The exact name of the issuer and its predecessor (if any).*

The name of the issuer is Leone Asset Management, Inc., (the "Issuer"). The Issuer was formerly known as Sloud, Inc., and prior to that, Sounsation!, Inc.

The Issuer owns all of the issued and outstanding shares of common stock of Leone Asset Management, Inc., a Nevada corporation.

Item II: *The address of the issuer's principal executive offices.*

The address of the Issuer's principal executive offices is 1723 Commerce Avenue 'N', St. Petersburg, FL 33716

Item III: *The jurisdiction(s) and date of the issuer's incorporation or organization.*

The Issuer was incorporated in the State of Nevada on October 10, 2005 under the name Sounsation!, Inc. On March 15, 2007 the name was changed to Sloud, Inc., and on April 4, 2013 changed to Leone Asset Management, Inc.

Part B Share Structure

Item IV: *The exact title and class of securities outstanding.*

The Issuer's only class of outstanding securities is Common Stock, par value \$.001 per share.

The CUSIP number of the Issuer's Common Stock is 526638101. The trading symbol of the Issuer's Common Stock is "LEON."

Item V: *Par or stated value and description of the security.*

A. Par Value

1. The Preferred Stock of the Issuer has a par value of \$.001 per share.
2. The Common Stock of the Issuer has a par value of \$.001 per share.

B. Common or Preferred Stock

1. Common Equity.

The Issuer is authorized to issue 500,000,000 shares of Common Stock, par value \$.001 per share. As of date hereof, 122,486,350 shares of Common Stock of the Issuer were issued and outstanding.

Each shareholder is entitled to one vote for each share of Common Stock owned of record. The holders of shares of Common Stock do not possess cumulative voting rights, which means that the holders of more than fifty percent of the outstanding shares voting for the election of directors can elect all of the directors, and in such

event the holders of the remaining shares will be unable to elect any of our directors. Except with respect to the election of directors and provided that appropriate notice has been given in accordance with the Bylaws, action may be taken without a meeting, if a written consent setting forth the action taken is signed by holders of not less than the minimum number of shares necessary to authorize the action at a meeting if all shares entitled to vote were present and voted. If the consent of all shares entitled to vote is not obtained, within ten days of obtaining the consent by a sufficient number of shares to approve the vote, subsequent notice must be given to holders who did not so consent.

Holders of outstanding shares of Common Stock are entitled to receive dividends out of assets legally available therefore at such times and in such amounts as the Board of Directors may from time to time determine. Upon the liquidation, dissolution, or winding up of the Company, the assets legally available for distribution to the shareholders will be distributable ratably among the holders of the shares outstanding at the time. Holders of the shares of Common Stock have no preemptive, conversion, or subscription rights, and shares are not subject to redemption.

2. Preferred Stock.

The Issuer is authorized to issue up to 20,000,000 shares of Preferred Stock, par value \$.001 per share, issuable in such series and bearing such voting, dividend, conversion, liquidation and other rights and preferences as the Board of Directors may determine. As of the date hereof, no shares of Preferred Stock of the Issuer were issued or outstanding. Any future issuances of Preferred Stock could dilute the voting rights and economic interests of holders of shares of Common Stock.

3. Describe any other material rights of common or preferred shareholders. Except, as otherwise described in this **Item V**, neither the common nor the preferred shareholders have any other material rights at this time.

Item VI: *The number of shares or total amount of the securities outstanding for each class of securities authorized.*

A. Preferred Stock

1. As of the date hereof, the Issuer had 20,000,000 shares of Preferred Stock, par value \$.001 per share, authorized.
2. As of the date hereof, no shares of Preferred Stock of the Issuer were issued or outstanding.

B. Common Stock

1. As of the date hereof, the Issuer had 500,000,000 shares of Common Stock, par value \$.001 per share, authorized.
2. As of the date hereof, 122,486,350 shares of Common Stock were issued and outstanding.
3. As of the date hereof, there were 1,850,000 freely tradable shares of Common Stock of the Issuer (public float).
4. As of the date hereof, there were 116 shareholders of record of the Common Stock

of Issuer.

Part C Business Information

Item VII: *The name and address of the issuer's transfer agent.*

The Issuer's transfer agent is Island Stock Transfer, Inc., 15500 Roosevelt Blvd., suite 301, Clearwater, Florida 33760. The telephone number of Island Stock Transfer is (727) 289-0010. Island Stock Transfer, Inc., is registered under the Securities Exchange Act of 1934.

Item VIII: *The nature of the issuer's business.*

The Company was incorporated in Nevada on October 10, 2005 under the name Sounsation! Inc. On March 15th, 2007, this name was changed to Sloud, Inc.

The Company was initially headquartered in Reston Virginia. It then moved to Falls Church, Virginia and has now relocated to its current location in St. Petersburg Florida. The Company was founded by Gene Sokolov, who assigned his intellectually property rights in certain technologies to the company at its inception in exchange for common stock in the Company. In November of 2005, the Company entered into Intellectual Property Acquisition Agreement and acquired a portfolio of technologies from Dr. Sergey Maruta in exchange for shares of the Company.

In November of 2011 the Company began the process of merging with Southwest Biofuels. Although the merger was announced, the merger was never fully consummated, Articles of Merger were never filed and in June of 2012 all efforts to complete the merger terminated. In June of 2012, Sloud acquired 100% of Leone Asset Management, Ltd., a Sierra Leone corporation that operates in Real Estate and Development as well as mineral Exploration and Export. In March of 2013, Sloud merged its subsidiary, Sloud Health, Inc., with Leone Holdings, Inc. the owner of JP Anderson, Ltd., in Sierra Leone. On April 2, 2013, Sloud filed for a name change to Leone Asset Management, Inc., in accordance with the state laws of Nevada and was filed and approved with FINRA in December of 2013. In December 2013, Leone Asset formed a subsidiary named Farmica Africa to complete a Joint Venture with Songo Lemon Grass, Limited. On January 6th 2014, Leone Asset sold its financial advisory subsidiary JPA Africa holdings, Inc., and all holdings and subsidiaries related to JP Anderson to focus on its agriculture and mining interests. On November 24, 2015, Leone Asset re-acquired JP Anderson S.L, Limited that owns all development and operational rights to a 300- acre granite quarry in Sierra Leone with estimated reserves of \$2 billion US dollars. On November 7, 2016, Leone Asset Management acquired Go Epic health, Inc. On December 20, 2016, Leone Asset Management acquired Sinol USA, Inc. On December 22, 2016, Leone Asset Management acquired ALM Research & Development.

The fiscal year for the Company ends 12/31. Leone Asset Management has never filed bankruptcy or been in receivership. The company has never defaulted on any material loan or financing.

Except as noted above, there have been no material reclassifications, mergers, consolidations or purchases or sales of a significant portion of the assets of either Company.

Except as noted above, there are no past, pending or anticipated stock splits, stock dividends, recapitalizations, mergers, acquisitions, spin-offs or reorganizations. There are no current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer. On March 15th, 2007, in connection with the name change to Sloud Inc., the number of authorized common stock was increased to 100,000,000. In March of 2007, the Company filed a Registration Statement with the Securities and Exchange Commission that became effective in July of 2008 at which time the Company began reporting. In July of 2010, the Company filed notice of its intent to stop reporting. On March 21, 2013, the number of authorized common stock was increased to 500,000,000.

A. Business Development

1. The form of organization of the Issuer.

The issuer is a Nevada corporation.

2. The year that the Issuer (or any predecessor) was organized.

The Issuer was organized in 2005.

3. The Issuer's fiscal year end date.

The Issuer's fiscal year ends on December 31.

4. Whether the Issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding.

The Issuer has not been subject to bankruptcy, receivership or any similar proceeding during the past three years.

5. Whether the Issuer has made any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets.

Except as described in this Item VIII above, the Issuer has not made any material classification, merger, consolidation or purchase or sale of a significant amount of assets during the past three years.

6. Any default in the terms of any note, loan, lease or other indebtedness or financing arrangement requiring the Issuer to make payments.

To the knowledge of the present management, the Issuer has not defaulted in the terms of any note, loan, lease or other indebtedness or financing arrangement requiring the Issuer to make payments during the past three years.

7. Any change of control of the Issuer.

Except as described in this Item VIII above, there has not been any change in control of the Issuer during the past three years securities.

8. Any increase of 10% or more of the same class of outstanding equity.

Except as described in this Item VIII above, there has not been any increase of 10% or more of the outstanding common stock of the Issuer during the past three years.

9. Any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization.

Except as described in this Item VIII above, there has not been any stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization involving the Issuer during the past three years.

10. Any delisting of the Issuer's securities by any securities exchange or deletion from the OTC Bulletin Board.

There has not been any delisting of the Issuer's securities by any securities exchange or deletion from the OTC Bulletin Board during the past three years.

11. *Any current, past, pending or threatened legal proceedings or administrative actions either by or against the Issuer that could have a material effect on the Issuer's business, financial condition or operations and any current, past or pending trading suspensions by a securities regulator.*

The Issuer is not a party to any pending or threatened legal proceedings or administrative actions either by or against the Issuer that could have a material effect on the Issuer's business, financial condition or operations or result in any trading suspension by a securities regulator.

B. Business of Issuer

Forward Looking Statements

Except for historical information, the matters discussed herein and in the Issuer's press releases and other public pronouncements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," "anticipate," "estimate" and similar expressions identify certain of such forward looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from historical results or from any results expressed or implied by such forward looking statements. Any forward looking statements speak only as of the date on which such statements are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied in such forward looking statements, whether as a result of new information, future events or otherwise.

Factors that could cause such results to differ materially from the results discussed in such forward looking statements include, without limitation: uncertainty of the Issuer's meeting its operational needs due to current working capital constraints; losses to date; no assurances of and uncertainty of profitability; need for additional equity investment and/or debt capital; no current agreements, arrangements, or understandings for such needed capital; no assurances of the Issuer successfully executing upon its business plan; substantial competition from companies having substantially greater financial, marketing and other resources than the Issuer, including name and brand recognition; the impact of competitive services and pricing; changing consumer tastes and trends; and no assurances of an active or sustained trading market in the Issuer's securities. Many of such factors are beyond the Issuer's control. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can management assess the impact of each such factor, or combination of factors, which may cause actual results to differ materially from those contained in any forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results anticipated in these forward looking statements will in fact occur. The Issuer undertakes no obligation to update any such forward-looking statements.

"We previously were a shell company, therefore the exemption offered pursuant to Rule 144 is not available. Anyone who purchased securities directly or indirectly from us or any of our affiliates in a transaction or chain

of transactions not involving a public offering cannot sell securities in an open market transaction."

Introduction

The Issuer, Leone Asset Management, Inc., a Nevada Corporation, is headquartered in, St. Petersburg Florida. Leone Asset Management owns and operates multiple subsidiaries that primarily operate in the manufacturing and distribution of health and dietary nutritional products. In addition, Leone owns additional subsidiaries that own assets and leases in Sierra Leone. The company intends to either operate or sell these assets in the coming years.

At Leone Asset Management, we strive to be a leader in any industry that we operate in. Our cutting edge management team is always on the look out for additional opportunities that make sense on both a business and personal level.

What We Do

Building long-standing and productive relationships is key to the success of Leone Asset and its subsidiaries. We strive to give our customers and clients cutting edge products and services with a personal touch.

The Issuer's primary and secondary SIC Codes.

SIC Code: 6719

Secondary Code: 2833

1. *Whether the Issuer has never conducted operations, is in the development stage or is currently conducting operations.*

The Issuer is currently a fully operating company.

2. *Whether the Issuer is or has at any time been a "shell company."*

3. *At one time, the Issuer was a "shell company" as that term is defined in Rule 405 promulgated by the Securities and Exchange Commission.*

4. *State the names of any parent, subsidiary or affiliate of the Issuer and its business purpose, its method of operation, its ownership and whether it is included in the financial statements attached to this Disclosure Statement.*

At present, the Issuer has a few wholly owned subsidiaries. A description of the business purpose and method of operation of the Subsidiaries is set forth in this Item VIII.B above. No financial statements are attached to this Disclosure Statement.

5. *The effect of existing or probable governmental regulations on the business.*

Both the manufacturing and distributing of supplemental health and nutrition products face substantial litigation and regulatory risks. Although we are and will continue to be diligent in the area of regulatory compliance, there is legal risk with respect to non-compliance with applicable legal and regulatory requirements and standards. Legal risk also includes contractual and commercial risk such as the risk that counterparty's performance obligations will be unenforceable. Although we

have not encountered these risks, firms operating in our industries in general have experienced actual or threatened legal claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages. Company's in our areas of business have also been involved in reviews, investigations and proceedings, both formal and informal, by governmental agencies relating to, among other things, accounting and operational matters, certain of which have resulted in adverse judgments, settlements, fines or other relief.

6. *An estimate of the amount spent during each of the last two fiscal years on research and development activities and, if applicable, the extent to which the cost of such activities are borne directly by customers.*

During the past two fiscal years, the Issuer and its Subsidiaries expended approximately \$300,000 on research and development activities.

7. *Costs and effects of compliance with environmental laws (federal, state and local).*

The costs and effects of our compliance with applicable environmental laws are material to our business and operations. In the sectors we operate in, we are required to have annual licenses and are under review on an ongoing basis with government bodies. Where the ongoing operating costs are not a burden to the company, fines could be substantial if the company is found to operate outside government guidelines.

8. *The number of total employees and the number of full-time employees.*

At present, we have 8 employees, which all are full-time.

Item IX: *The nature of products or services offered.*

A. *Principal products or services and their markets*

Our Subsidiary Go Epic Health, Inc., is a nutritional product holding company which owns the intellectual property and worldwide manufacturing and distribution rights to multiple products including Cholesterade®, a natural cholesterol reducing product created by the late Dr. Robert Cade, creator of Gatorade®.

Go Epic's subsidiary, American Retail Alliance, markets and distributes Cholesterade® as well as other new and innovative consumer goods through the nation's largest retail pharmacy chain stores, independent drug and health food stores, multi-level organizations and product specific catalogs.

ALM Research & Development is a company specializing in the formulation of innovative nutraceutical and cosmeceutical products for both the consumer and professional marketplace and has had several products marketed through major national chains. A major focus of ALM for the past 6 years has been creating a more efficient method to deliver compounds to the body. As a result, ALM has created a novel platform delivery technology, which is fully patent-pending. It has been clinically demonstrated to increase permeation and duration of activity of compounds through transdermal delivery as well as enhance active compound

uptake and bioavailability when applied orally. The technology not only holds multiple compounds and transports them into the body with unprecedented efficiency, but also has a major positive impact on surrounding physiology that is the target of delivery for active ingredients. This technology is in use with a number of topical products in the medical/aesthetic field.

Subsidiary, Sinol USA, Inc., is a healthcare company dedicated to exceeding the needs of today's consumers by creating healthcare products using 100% all natural ingredients. With so many prescription medications adding additional health risks, it is imperative that people have a natural choice when it comes to their own health care. By understanding the need for healthier medicines, Sinol has raised the bar, by formulating a unique combination of clean, old-fashioned ingredients with new innovative technology. We have created the first capsaicin based, FDA approved, over the counter nasal spray for fast relief from allergy and sinus congestion and headaches of all degrees and types. Our dedication to providing a healthier medical alternative has been widely recognized and applauded by doctors and medical communities, and it is our mission to heal our customers suffering with clean all natural nasal spray products. We believe in giving our customers fast relief and peace of mind in knowing that they have made the right choice in using our all-natural products.

Our subsidiary, JP Anderson S.L. Limited, was founded to provide unparalleled service within the Mineral Exploration and Mineral Export business in Sierra Leone. We take a conservative, disciplined approach to managing our assets. At this time, the main focus of JP Anderson is the management and initial planning of operating a 300 - acre granite quarry that has approximately \$2 billion US dollars in granite within the quarry.

Leone Asset subsidiary Farmica Africa owns a Lemon Grass Nursery in Sierra Leone and intends to operate agriculture properties that specialize in Lemon Grass production.

Principal Product Information

Sinol USA - Sinol is clinically proven and doesn't have major side effects that most competitors have like rebound and drowsiness.

Sinol USA, Inc is changing the way consumers think about health care today with our unique formulas of Sinol branded, clean and natural nasal spray products. Sinol is a high growth over the counter healthcare company deeply engaged in the development and marketing of products that utilize old fashioned methods to relieve even the most severe cases and types of headaches, chronic sinus problems, sinusitis and allergies, using the cleanest and most natural ingredients available to deliver pain relief in minutes. Sinol can be purchased on line or by visiting one of our retailers.

Get Sinus, Headache and Allergy Relief in Minutes Not Hours!

How Sinol works on Headaches

Most headaches are caused by a spasm of blood vessels around the eyes and across the forehead. Sinol nasal spray is a fast acting, all natural and gentle remedy that relaxes the muscles and blood vessels. Sinol can relieve headaches when they first begin and is extremely effective for headaches of all types. Sinol works faster than a pill or a liquid and can relieve headaches in minutes.

How Sinol works on Allergies and Sinus

Sinol's main ingredient, Capsaicin, is found in the pepper plant. The Capsaicin in Sinol Allergy nose spray desensitizes the mucous membranes in the nose making them less irritated by airborne particles and allergens. It helps to relieve allergies, congestion and sinus headaches fast. Capsaicin prevents allergy triggers while our other natural ingredients keep your nasal passages moist, clean and free of bacteria and infection. Our combination of Capsaicin and other all natural ingredients is what makes Sinol All Natural Allergy spray the most highly effective nasal sinus spray on the market today for allergy relief, headache relief, sinus and sinusitis treatment. Sinol does not dry out the nose like antihistamines and decongestants. Neti Pots and other saline sprays can dry out your nose and create soreness and cracking. Sinol moisturizes with aloe and eucalyptus to help keep your nasal passages moist, healthy and bacteria free.

Sinol's All Natural Ingredients

Aloe Vera Extract, Eucalyptus Oil, Rosemary Extract, Sea Salt, Vitamin C and Capsicum 4x

Mission Statement

Sinol USA, Inc., is a healthcare company dedicated to exceeding the needs of today's consumers by creating healthcare products using 100% all natural ingredients. With so many prescription medications adding additional health risks, it is imperative that people have a natural choice when it comes to their own health care. By understanding the need for healthier medicines, Sinol has raised the bar, by formulating a unique combination of clean, old-fashioned ingredients with new innovative technology. We have created the first capsaicin based, FDA approved, over the counter nasal spray for fast relief from allergy and sinus congestion and headaches of all degrees and types. Our dedication to providing a healthier medical alternative has been widely recognized and applauded by doctors and medical communities, and it is our mission to heal our customers suffering with clean all natural nasal spray products. We believe in giving our customers fast relief and peace of mind in knowing that they have made the right choice in using our all-natural products.

Privacy Policy

Sinol USA, Inc. recognizes the importance of protecting the privacy of all information provided by users of our web site. We have created this policy with a fundamental respect for our customer's right to privacy and to guide our relationships with our

customers. We assure you that any personal information you provide will never be shared or sold.

Refund Policy

We will issue a refund within 90 days if Sinol does not work for you. This is our guarantee.

Return Policy

To return product to us, call 1-203-270-4167.

Cholesterade® - Cholesterade® was created by Dr. J. Robert Cade, the inventor of Gatorade®. Cholesterade® provides a natural, delicious and economical solution to help meet NIH requirements for therapeutic lifestyles changes using non-drug intervention to lower cholesterol prior to consideration of statin intervention. Without making any other lifestyle changes, remarkable results were achieved in only 8 weeks.

In an 8 week study performed by Dr. Cade participants achieved amazing results without altering their lifestyle or taking harmful drugs. Participants each drank 1-8 ounce glass of Cholesterade® with each meal and one at bedtime.

In 8 weeks, the participants achieved

Total Cholesterol (TC) -17.9%

LDL Cholesterol (LDLC) -21.4%

HDL Cholesterol (HDLC) +12.9%

HDLC/LDLC Ratio +44.0%

Triglycerides -50.0%

- Our recommended daily dose is 2-3 times per day. Individual results may vary from those of the original Dr. Cade study where participants daily dose was 4 times per day.

Note: “Gatorade® is a registered trademark of Stokely-Van Camp, Inc. GO EPIC is not affiliated with Gatorade® or Stokely-Van Camp, Inc.”

Directions: Adults, stir 2 level scoops (included) into 8 ounces of water or juice 2 times a day (not recommended for carbonated beverages). Store in a cool dry place at 59-86 F (15-30C)

Ingredients: Organic Acacia Fiber, Sugar, Maltodextrin, Citric Acid, Natural Flavors, Enzymes, Rebaudioside A, Silica, Soy Lecithin Phospholipids (Go-Somes™)
Made without wheat, gluten, salt, yeast, dairy, nuts, preservatives, animal products, artificial colors, artificial flavors, or artificial sweeteners.

GMO Free, 100% Vegetarian

Supports Digestive Competence†

Go-Some Delivery Technology is based on Clinically Researched Patent-pending technology utilized to enhance nutrient bioavailability and duration of nutrient activity*

Cholesterade® Soluble Acacia Fiber is an excellent source of dietary fiber. Each serving provides 7 grams of 20-35 grams of the daily recommended fiber by the Academy of Nutrition and Dietetics to promote good digestion, colon and intestinal health.

Cholesterade® also:

- Promotes pro-biotic function helping over all gut health
- Helps curb appetite safely promoting weight management
- Helps aid digestion
- Easily dissolves in liquids
-

Cholesterade® does not contain:

- Preservatives
- Artificial ingredients
- Gluten

KEEP OUT OF REACH OF CHILDREN.

WARNING: Consult your physician before using this or any product if you are pregnant, nursing, taking any medication or have a medical condition.

IMPORTANT: Drink at least a full glass of liquid (minimum 8 oz. suggested) when consuming this product as choking can occur. Do not use if you have difficulty swallowing or obstructed bowel.

At this time we have several additional products under development including Recuperade®, a superior hydration formula and Go Muscle Recovery Shakes and Bars that were also created by Dr. J. Robert Cade, the creator of Gatorade®.

B. Distribution methods of the products or services

It is our intent to primarily use multiple online websites and retail outlets such as pharmacies, grocery stores and specialty nutrition stores to distribute our products and services. However, we will additionally advertise in local paper, radio, television mediums as well as our corporate web sites.

C. Status of any publicly announced new product or service

We have publicly announced the launch of our flagship product Cholesterade.

D. Competitive business conditions, the Issuer's competitive position in the industry and methods of competition.

Competition in the Health and Dietary Supplement industry is based primarily upon:

- Brand name recognition;
- Availability of financial resources;
- Quality of products or services offered;
- Reviews received for products or services from independent reviewers who publish in magazines, websites, newspapers and other industry publications;
- The price of products and services; and
- The number of comparable products or services then available.

We will rely on what we believe to be our superior marketing and sales abilities and our management's experience to compete within our market segments. However, we may not be able to effectively compete in these intensely competitive markets. Moreover, some of our competitors have longer operating histories, larger customer bases and greater financial, marketing, service, support, technical and other resources, affording them the ability to undertake more extensive marketing campaigns, than we can. Furthermore, competition from new market entrants may increase as the various financial markets expand with time.

E. Sources and availability of raw materials and the names of principal suppliers

At this time, all necessary ingredients and raw materials that we utilize to manufacture our product offering are readily available through multiple vendors throughout the US.

F. Dependence on one or a few major customers

We are not dependent on one or a few major customers for sales in Leone Asset

Management.

G. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration

We rely on a combination of trademarks, copyrights, trade secrets and contract law rights.

9. Patents

Our subsidiary ALM R&D currently has a patent-pending for their novel delivery technology.

10. Copyright/Trademark

In order to establish and protect our brand names as part of our intellectual property assets, we will be applying for International trademark protection for our logos, Leone Asset Management, Go Epic Health, Cholesterade, Recuperade and additional products.. As of the date of this disclosure document, all of our registrations are in the preliminary stages of the application process or remain pending.

11. Trade Secrets

Whenever we deem it important for purposes of maintaining competitive advantages, we will require parties with whom we share, or who otherwise are likely to become privy to, our trade secrets or other confidential information to execute and deliver to us confidentiality and/or non-disclosure agreements. Among others, this may include employees, consultants and other advisors, each of whom we would require execute such an agreement upon commencement of their employment, consulting or advisory relationships. These agreements will generally provide that all confidential information developed or made known to the individual by us during the course of the individual's relationship with us is to be kept confidential and not to be disclosed to third parties except under specific circumstances. As of the date of this Memorandum, we have executed confidentiality and/or non-disclosure agreements with our executive officers or directors.

H. The need for governmental approval of principal products or services and the status of any governmental approvals

As we expand the distribution of our product offering to include international destinations, we may be subject to extensive regulation in the jurisdictions in which we desire to distribute certain products. Although we have developed and will continue to foster excellent relationships with the local governments in the countries in which we conduct our business, we may be subject to extensive regulation and face the risk of significant intervention by regulatory authorities in such jurisdictions. Any determination by local regulators that we have not acted in compliance with the application of local laws in a particular market or our failure to develop effective working relationships with local regulators could have a significant and negative effect on our business in that market as well as on our

reputation. New laws or regulations or changes in enforcement of existing laws or regulations applicable to our businesses or those of our clients may also adversely affect our businesses. Regulatory changes could lead to business disruptions, could require us to change certain of our business practices and could expose us to additional costs and liabilities as well as reputational harm. We are also subject to the risk that transactions we structure might not be legally enforceable in all cases.

Item X: *The nature and extent of the issuer's facilities.*

Executive Office

Our principal executive offices are located at 1723 Commerce Ave 'N', St. Petersburg, FL 33716. Our telephone number is (727) 581-1500. Our website address is www.leoneasset.com.

Part D Management Structure and Financial Information

Item XI: *The name of the chief executive officer, members of the board of directors, as well as control persons.*

A. Officers and Directors

Our director and officers are as follows:

James Price – Chairman/CEO

Mr. Price himself is perhaps best described as a true entrepreneur with over 25 years of experience in multiple industries including the financial services industry. After attending college at Eastern Washington University, Mr. Price served 3 years in the U.S. Army. Upon his honorable discharge he moved to Maryland and began his career as a successful stockbroker. Over a 10-year span as a broker and office Principal, he worked at JW Gant, Cohig and Associates, AG Edwards and Sons and Global Financial. Licenses held; series 7, 63, 24 life and health.

Over his extensive management career, Mr. Price has either formed, been President, CEO and/or interim CEO's of several public and private companies including: JP Anderson, Greenzone Ventures, Papa Bello Enterprises, Benacquista Galleries, Columbia Financial Group, UC Hub, Leone Asset Management, Global Brands International, Global Mobile Technologies, Trunk Health and others.

Mr. Price founded the Children of God Orphanage to assist with the crisis in Sierra Leone and has formerly sat on the board of directors for the YMCA, was the Chairman of the I AM Foundation and currently is the Chairman and co-founder of the Leone Asset Foundation and is the Founder and Chairman of The Children of God Orphanage.

Woody Junot – President/Director

Mr. Junot is a proven Successful Financial/Managerial executive whom through his 30-year plus career has extensive experience as a business owner, financial planner, and real estate and mortgage broker. Mr. Junot possesses a strong entrepreneurial

spirit applying it to everything he does. He brings to Go Epic Health many years of experience and a successful track record as a businessman and entrepreneur.

Mr. Junot owned and operated an investment relations firm, Emerald Resource Group Inc. for 10 years and concurrently, he incorporated, built and sold, several entities including two real estate companies, a business brokerage company and a commercial lending company. Mr. Junot attended The Academy of Advanced Traffic and Transportation in Philadelphia Pa, in his early years, and attended several management/consulting institutions to gain his extensive leadership skills and abilities. During Mr. Junot's career he has possessed many industry specific licenses, mortgage brokerage, real estate, series 7 and series 63 investment licenses.

Eric Mader – Director

Mr. Mader is a Seasoned Corporate Executive/General Counsel with solid and progressive experience in new business development, Expertise in start-ups, fund raising, corporate creation, consumer packaged goods and services, business-to-business markets and International markets management. Mr. Mader has an established track record of positioning companies, brands, products and people for accelerated growth. He has extensive sales and marketing background across multiple industries. His areas of expertise include being highly skilled in collaborating with all members of the organization to achieve business and financial objectives. He is accomplished at developing long-term relationships with clients, generating loyalty above and beyond the sales relationship. Mr. Mader is adept in streamlining financial processes, enhancing productivity levels and introducing process improvements.

Mr. Mader is highly regarded as a forward thinking and dynamic executive with 15+ years of cross-functional experience leading teams in progressively challenging roles across diverse environments and industries from entrepreneurial start-ups to large, corporations to privately owned businesses.

12. Employment Agreements

At this time the issuer has no employment agreements in place with its officers. The issuer has plans to enter into an employment agreement with all key personnel in 2018.

13. Stock Ownership

James Price is the beneficial owner of 23,527,700 shares of Common Stock of the Issuer, that constitutes approximately 19% of the number of issued and outstanding shares of Common Stock of the Issuer. Woody Junot is the beneficial owner of 5,000,000 shares of Common Stock of the issuer, that constitutes approximately 4% of the number of issued and outstanding shares of Common Stock of the Issuer.

B. Legal/Disciplinary History

None of the Issuer's executive officers, directors or control persons have in the last

five years, been the subject of:

1. A conviction in a criminal proceeding or named as defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment or decree not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended, or otherwise limited such person's involvement in any type of business, securities, commodities or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodities Futures Trading Commission or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Disclosure of Family Relationships

There are no family relationships, by blood, marriage or adoption, among or between any of our directors, officers or beneficial owners of more than five percent of our outstanding shares of Common Stock.

D. Disclosure of Related Party Transactions

As of the date of this disclosure document there has been no related party transactions with the Issuer.

E. Disclosure of Conflicts of Interest

None.

Item XII: *Financial information for the issuer's most recent fiscal period.*

Financial statements of the Issuer are being prepared at present. No financial statements of the Issuer are being supplied at this time.

Item XIII: *Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.*

Financial statements of the Issuer are being prepared at present. No financial statements of the Issuer are being supplied at this time.

Item XIV: *Beneficial Owners.*

The following table sets forth information regarding the beneficial ownership of each person known by the Issuer to beneficially own more than five percent of the outstanding shares of Common Stock of the Issuer as of the date hereof:

James Price is the beneficial owner of 23,527,700 Common shares.

Charles Ben Bates, Jr., is the beneficial owner of 20,000,000 Common shares.

Brett Philips is the beneficial owner of 7,873,510 Common shares.

Tony Khodadad is the beneficial owner of 13,000,000 Common Shares.

Item XV: *The name, address, telephone number and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:*

1. *Investment Banker:* Not Applicable
2. *Promoters:* Not Applicable
3. *Counsel:* Jeffrey Rinde, Esq., CKR Law, 1330 6th Avenue, New York, New York 10019. (212) 259-7300
4. *Accountant:* Russ Boyer, Biz CFO, 20321 SW Birch St, Suite 200, Newport Beach CA 92660
5. *Public Relations Consultant(s):* Not Applicable
6. *Investor Relations Consultant:* Not Applicable
7. *Other Advisor(s):* Not Applicable

Item XVI: *Management's Discussion and Analysis or Plan of Operations.*

Since appropriate financial statements of the Issuer have not yet been prepared, it is not possible at present to prepare a management's discussion and analysis of financial condition and results of operation.

Part E: Issuance History

Item XVII: *List of securities offerings and shares issued for services in the past two years.*

None.

Part F: Exhibits

Item XVIII: *Material Contracts.*

The Company through its subsidiaries has entered into exclusive agreements. JP Anderson S.L., Limited has the exclusive agreement to operate and control a 300-acre Granite Quarry in Sierra Leone. This agreement is between JP Anderson S.L., Ltd., and the Kaimeh Land Holding families of Gangama. In addition, subsidiary Farmica Africa, Ltd., has the exclusive agreement with Songo Lemon Grass, Limited to grow from its nursery, manufacture and market Lemon Grass and its products.

Item XIX: *Articles of Incorporation and Bylaws.*

The Amended and Restated Articles of Incorporation of the Issuer and the Amended and Restated Bylaws of the Issuer have been uploaded on OTCMarkets.com.

Item XX: *Purchases of Equity Securities by the Issuer and Affiliated Purchasers.*

Except as set forth in Item VIII above, the Issuer has not purchased any equity securities of the Issuer.

Item XXI: *Issuer's Certifications.*

I, James Price, certify that: I have reviewed the Initial Company Information and Disclosure Statement dated June 26, 2017 of Leone Asset Management, Inc., a Nevada corporation; Based on my knowledge, this disclosure statement does not

contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and Based on my knowledge, the financial statements, and other information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: June 26, 2017